Is Pfizer a "Buy" After Crashing Back to Earth?

This pandemic darling isn't so popular anymore. [Shield] AN OXFORD CLUB PUBLICATION [Wealthy Retirement]( [View in browser]( SPONSORED ["Weird" Savings Account Boost (Seniors Shocked)]( [Boost_Income]( "Magic Code" FORCES banks to pay you up to [255 times MORE cash interest]( (Give this code to your bank ASAP.) [Show Me the Code!]( [THE VALUE METER]( [Is Pfizer a "Buy" After Crashing Back to Earth?]( [Anthony Summers, Director of Trading, The Oxford Club]( [Anthony Summers]( Last week, a number of you messaged me to extend a warm welcome back and to congratulate me on my new role here at The Oxford Club. Many thanks to all of you for your kind words and encouragement. It certainly feels good to be back at the Club, and I look forward to sharing my honest thoughts with you, as I've always done in years past. In addition to the niceties, I also received many requests to run certain stocks through The Value Meter. Today's stock is one such example. Pfizer (NYSE: PFE), one of the world's largest drugmakers, became a Wall Street darling during the pandemic as demand surged for its COVID-19 vaccine and booster shots. But now, with that health crisis mostly behind us, shareholders have seen their fortunes reverse. Since hitting an all-time high a couple of years ago, Pfizer's stock price has been cut in half, reverting to pre-pandemic levels. This steep drop now has many investors wondering whether Pfizer has "value" written all over it. [Chart: Pfizer]( [View larger image]( However, it's important not to mistake a lower price for inherent value. Let's look more closely at the company's financials to see why. Again, as global demand for its COVID-related products has waned, Pfizer's revenues and EBITDA (earnings before interest, taxes, depreciation and amortization) have unsurprisingly retreated back to their pre-pandemic levels. [Chart: Revenue and Earnings Have Tailed Off Since COVID]( [View larger image]( You can see that the company's growth in both revenue and EBITDA was tepid for several years before spiking during the pandemic. Meanwhile, free cash flow generation has been steadily deteriorating for the past couple of years, and it has now fallen significantly below pre-pandemic levels. [Chart: Free Cash Flow Well Below Pre-COVID Levels]( [View larger image]( Simply put, both the euphoria and the exceptional financial performance that buoyed Pfizer's stock price have vanished. And investors know it. Hence the sell-off. The deep cut in the stock price means the market is rightfully pricing in the post-pandemic reality of Pfizer's core business, which happens to look a lot like it did before the pandemic. But has the stock fallen enough that it's now become undervalued? [Go Here to Finish Reading]( [The Oxford Club's Wealth, Wine and Wander Tour of Spain - Barcelona, Granada, Seville and Madrid, June 6-16, 2024 (plus special extension through June 21)]( SPONSORED [The #1 Energy Passive Income Investment for 2024]( It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2024. [CLICK HERE TO FIND OUT WHAT IT IS]( BUILD AND PROTECT YOUR WEALTH [Here are Three Steps You Need to Take to Protect and Grow Your Money When America Is Threatened With Mass Unemployment. Watch This Before AI Goes Supernova.]( [The True "Burden" of Wealth]( [Whatever You Do, DON'T Invest in the Wrong AI Companies.]( [My Top 2 Strategies for Risk Management]( MORE FROM WEALTHY RETIREMENT [Article]( [China's Pain Could Be the Rest of the World's Gain]( [Article]( [The Boundless Power of Compounding]( [Article]( [Clarivate Is a Cash Flow Machine!]( [Article]( [Brookfield Renewable Corp.: Can It Afford Its 5.5% Yield?]( [Facebook]( [Facebook]( [LinkedIn logo]( [LinkedIn]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AThis pandemic darling isn%27t so popular anymore...%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AThis pandemic darling isn%27t so popular anymore...%0D%0A%0D [Push Alert]( [Push Alert]( SPONSORED [BREAKING: Major Stock Price Upgrade to $280!]( [Putin on Stage]( Source: [Wikimedia Commons]( Thanks to a HUGE blunder by Vladimir Putin... Wall Street analysts say one unique energy stock is on track to soar from $30 to $280. [Check out the unusual situation right here.]( [The Oxford Club]( You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Wealthy Retirement]( | [Unsubscribe]( © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [877.808.9795](#) | International: [+1.443.353.4621](#) [Oxfordclub.com]( Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.